A Phase I Study of SGN-40 (anti-huCD40 mAb), Lenalidomide (Revlimid, cc 5013), and Dexamethasone in Patients with Multiple Myeloma (MM).

Trial Profile

A Phase I Study of SGN-40 (anti-huCD40 mAb), Lenalidomide (Revlimid, cc 5013), and Dexamethasone in Patients with Multiple Myeloma (MM).

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Nov 2014

At a glance

  • Drugs Dacetuzumab (Primary) ; Dexamethasone; Lenalidomide
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Sponsors Seattle Genetics
  • Most Recent Events

    • 28 Jun 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 28 Jun 2010 Actual end date (May 2010) added as reported by ClinicalTrials.gov.
    • 08 Dec 2009 Results have been presented at the 51st Annual Meeting of the American Society of Hematology (ASH 2009), according to a Seattle Genetics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top